Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts.
Vigil Neuroscience, Inc. Frequently Asked Questions
What is the ticker symbol for Vigil Neuroscience, Inc.? What does VIGL stand for in stocks?
VIGL is the stock ticker symbol of Vigil Neuroscience, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Vigil Neuroscience, Inc. (VIGL)?
As of Fri Dec 20 2024, market cap of Vigil Neuroscience, Inc. is 69.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of VIGL stock?
You can check VIGL's fair value in chart for subscribers.
Is Vigil Neuroscience, Inc. a good stock to buy?
The fair value guage provides a quick view whether VIGL is over valued or under valued. Whether Vigil Neuroscience, Inc. is cheap or expensive depends on the assumptions which impact Vigil Neuroscience, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIGL.